Dr. Vikram Lotwala- Expert in Bariatric & Hernia Surgery
Treasurer, South Gujarat Surgeons Society | E.C Member, Gujarat Chapter of ASI | E.C Member, Obesity Surgery Society of India
Living with obesity or being overweight is not just a cosmetic concern — it is a chronic medical condition that increases the risk of heart disease, type 2 diabetes, stroke, joint problems, and several other serious health issues. For patients who have struggled with diet and exercise alone, a new generation of weight loss medications is transforming outcomes. These drugs, particularly the GLP-1 receptor agonists, offer clinically proven results when prescribed under expert medical supervision.
Dr. Vikram Lotwala is a leading bariatric surgeon in Surat, Gujarat, and a Principal Investigator (P.I.) for global pharmaceutical companies including Eli Lilly, Novo Nordisk, and Glenmark. He is the only bariatric surgeon in Surat, Gujarat, authorized to conduct clinical trials for newer weight loss medicines — making him uniquely qualified to guide patients through the latest pharmacotherapy options for obesity.
Understanding Obesity — When Is Medical Treatment Recommended?
Not every patient with excess weight requires medication. Treatment decisions are based on Body Mass Index (BMI) and the presence of weight-related comorbidities. Here is a clinical guideline followed internationally:
| BMI Range | Lifestyle Modification | Pharmacotherapy | Surgery |
|---|---|---|---|
|
25–26.9 kg/m² |
✔ Recommended |
– |
– |
|
27–29.9 kg/m² |
✔ Recommended |
With adiposity-related complications |
— |
|
30–34.9 kg/m² |
✔ Recommended |
✔ Recommended |
With complications, when medical & lifestyle management is insufficient |
|
35–39.9 kg/m² |
✔ Recommended |
✔ Recommended |
With adiposity-related complications |
|
≥40 kg/m² |
✔ Recommended |
✔ Recommended |
✔ Recommended |
What Are GLP-1 Receptor Agonist Drugs?
GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of injectable medications originally developed for type 2 diabetes that have shown remarkable results in medical weight management. They work by:
- Mimicking the natural GLP-1 hormone your gut releases after eating
- Reducing appetite and increasing the feeling of fullness (satiety)
- Slowing gastric emptying so you feel satisfied longer
- Improving blood sugar control and reducing cardiovascular risk
These are not “magic shots” — they are evidence-based, FDA-approved medications that work best as part of a comprehensive plan that includes a reduced-calorie diet, physical activity, and ongoing medical supervision.
Weight Loss Medications Available Under Dr. Vikram Lotwala's Guidance
Semaglutide is one of the most extensively studied GLP-1 receptor agonists for weight loss. Wegovy (semaglutide 2.4 mg) is specifically approved for chronic weight management in adults with:
- BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity, OR
- BMI ≥30 kg/m² (obesity) with no requirement for a weight-based comorbidity
Clinical trials have shown an average weight reduction of 15–17% of body weight. Beyond weight loss, semaglutide 2.4 mg is also indicated to reduce the risk of major adverse cardiovascular events — including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — in adults with established cardiovascular disease and obesity or overweight.
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It targets two incretin hormones simultaneously, making it one of the most powerful weight loss drugs available today. In clinical studies, patients lost up to 20–25% of their body weight. Marketed as Mounjaro and Yurpeak, this medication is changing the landscape of obesity pharmacotherapy.
Glipiq is an emerging weight loss medicine from Glenmark Pharmaceuticals. Dr. Vikram Lotwala, as a Principal Investigator and panel member for Glenmark, has direct involvement in evaluating this drug’s efficacy and safety profile for Indian patients.
You may be a suitable candidate for GLP-1 based weight loss medications if you:
- Are 18 years or older
- Have a BMI of 27 kg/m² or higher with a weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia, or sleep apnoea
- Have a BMI of 30 kg/m² or higher, even without associated medical conditions
- Have not achieved adequate weight loss through diet and exercise alone
Dr. Vikram Lotwala conducts a thorough clinical evaluation — including blood work, metabolic assessment, and a complete medical history — before recommending any pharmacotherapy.
Dr. Vikram Lotwala is not just a prescriber of these medications — he is actively involved in shaping the future of obesity treatment in India.
- Principal Investigator for clinical trials conducted by Eli Lilly, Novo Nordisk, and Glenmark — companies behind modern obesity medicines such as Mounjaro, Wegovy, and other emerging therapies
- The only bariatric surgeon in Surat authorized to conduct trials for newer weight loss medicines
- Panel member and speaker for leading pharmaceutical companies, regularly conducting educational seminars for doctors on GLP-1 drugs and obesity pharmacotherapy
- Combines surgical expertise with deep knowledge of medical weight management, offering a 360-degree approach — from lifestyle modification and medications to bariatric surgery when required
When your doctor is directly involved in clinical research, you benefit from expertise that goes far beyond a routine prescription.
1. Initial Consultation
Detailed assessment of your weight history, BMI, metabolic health, and any existing medical conditions.
2. Personalized Treatment Plan
Based on your clinical profile, Dr. Vikram Lotwala recommends the most suitable medication, dosage, and lifestyle changes.
3. Supervised Medication Start
Treatment is started at a low dose and gradually increased to minimize side effects.
4. Ongoing Monitoring
Regular follow-ups to track progress, adjust dosage, monitor blood tests, and address concerns.
5. Long-Term Management
Obesity is a chronic condition. Ongoing support helps maintain long-term results.
Frequently Asked Questions (FAQ)
Are GLP-1 weight loss injections safe?
Yes. Medicines such as semaglutide and tirzepatide have undergone extensive clinical trials and regulatory review. Side effects are usually mild and manageable under medical supervision.
How much weight can I expect to lose?
Results vary, but studies often report average weight loss of 15–25% of body weight over 12–18 months, depending on the medication and individual response.
Do I still need diet and exercise?
Absolutely. These medications work best alongside a calorie-controlled diet and increased physical activity.
Can I take these medicines if I have diabetes?
Many GLP-1 medicines were originally developed for type 2 diabetes and may help patients managing both conditions. A full medical evaluation is essential first.
Is this treatment available in Surat?
Yes. Dr. Vikram Lotwala offers comprehensive medical weight management including GLP-1 therapies in Surat.
